SIGHT Gensight Biologics SA

GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025

Regulatory News:

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that new scientific data and analyses on the gene therapy LUMEVOQ® will be presented at the 51st Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS) in Tucson, Arizona, USA (March 15-20, 2025).

Leading Leber Hereditary Optic Neuropathy (LHON) Key Opinion Leaders will share new data on predictive factors of response to LUMEVOQ® treatment; on a comparison of the treatment outcomes from idebenone and LUMEVOQ®; on real-world experience with LUMEVOQ®; and on long-term outcomes from bilateral treatment with the gene therapy.

Poster presentation: “Predictive Factors of Improved Final Visual Outcome in Patients with Leber Hereditary Optic Neuropathy Treated with Lenadogene Nolparvovec Gene Therapy”

  • Presenter: Robert C. Sergott, MD, Wills Eye Hospital, Philadelphia, USA
  • Poster Number 209
  • Time: Monday, March 17th, 2025, 5:00 pm – 6:00 pm (MDT)
  • Location: Arizona Ballroom 1-6

Poster presentation: “Efficacy of Lenadogene Nolparvovec Gene Therapy Versus Idebenone: Two Matched Adjusted Indirect Comparisons”

  • Presenter: Patrick Yu-Wai-Man, MD, PhD, University of Cambridge, Moorfields Eye Hospital, and the UCL Institute of Ophthalmology, UK
  • Poster Number 186
  • Time: Monday, March 17th, 2025, 6:00 pm – 7:00 pm (MDT)
  • Location: Arizona Ballroom 1-6

Poster presentation: “Efficacy and Safety of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy in the Real-Life Setting

  • Presenter: Mark L. Moster, MD, Wills Eye Hospital, Philadelphia, USA
  • Poster Number 12
  • Time: Sunday, March 16th, 2025, 2:00 pm – 3:00 pm (MDT)
  • Location: Arizona Ballroom 1-6

Platform presentation: “Long-Term Outcomes of Bilateral Injection of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy”

  • Presenter: Nancy J. Newman, MD, Emory University School of Medicine, Atlanta, USA
  • Scientific Platform Session I
  • Time: Monday, March 17th, 2025, 11:45 am – 12:00 pm (MDT)
  • Location: Tucson Ballroom

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

About Leber Hereditary Optic Neuropathy (LHON)

Leber Hereditary Optic Neuropathy (LHON) is a rare maternally inherited mitochondrial genetic disease, characterized by the degeneration of retinal ganglion cells that results in brutal and irreversible vision loss that can lead to legal blindness, and mainly affects adolescents and young adults. LHON is associated with painless, sudden loss of central vision in the 1st eye, with the 2nd eye sequentially impaired. It is a symmetric disease with poor functional visual recovery. 97% of subjects have bilateral involvement at less than one year of onset of vision loss, and in 25% of cases, vision loss occurs in both eyes simultaneously.

About LUMEVOQ® (GS010; lenadogene nolparvovec)

LUMEVOQ® (GS010; lenadogene nolparvovec) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, arising from research conducted at the Institut de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). The gene of interest is transferred into the cell to be expressed and produces the functional protein, which will then be shuttled to the mitochondria through specific nucleotidic sequences in order to restore the missing or deficient mitochondrial function. “LUMEVOQ” was accepted as the invented name for GS010 (lenadogene nolparvovec) by the European Medicines Agency (EMA) in October 2018. LUMEVOQ® (GS010; lenadogene nolparvovec) has not been registered in any country at this stage.

EN
17/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Gensight Biologics SA

 PRESS RELEASE

GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2025

PARIS--(BUSINESS WIRE)-- Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that new scientific data and analyses on the gene therapy LUMEVOQ® will be presented at the 51st Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS) in Tucson, Arizona, USA (March 15-20, 2025). Leading Leber Hereditary Optic Neuropathy (LHON) Key Opinion Leaders will share new data...

 PRESS RELEASE

GenSight Biologics annonce des communications scientifiques sur LUMEVO...

PARIS--(BUSINESS WIRE)-- Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives de la rétine et du système nerveux central, annonce aujourd’hui que de nouvelles données et analyses scientifiques relatives à la thérapie génique LUMEVOQ® seront présentées lors du 51e Congrès Annuel de la North American Neuro-Ophthalmology Society (NANOS) qui se tient à Tucson, Arizona, Etats-Unis, du 15 au 20 mars 2025. Des lea...

 PRESS RELEASE

GenSight Biologics annonce un financement d’un montant d’environ 0,9 m...

PARIS--(BUSINESS WIRE)-- Regulatory News: CE COMMUNIQUE DE PRESSE N'EST PAS DIFFUSE ET DES COPIES NE PEUVENT PAS ETRE DISTRIBUEES OU ENVOYEES, DIRECTEMENT OU INDIRECTEMENT, AUX ETATS-UNIS, AU CANADA, EN AFRIQUE DU SUD, AU JAPON OU EN AUSTRALIE. GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME) (la "Société"), une Société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives de la rétine et les troubles du système nerveux central, a annoncé aujourd'hui un financement par le b...

Baptiste Salaville ... (+4)
  • Baptiste Salaville
  • Charlotte Vaisse
  • Emmanuel Matot
  • Marc Lavaud
NDX1 NORDEX SE
IPS IPSOS
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
SOP SOPRA STERIA GROUP SA
SLB.N SCHLUMBERGER NV
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
GTT GAZTRANSPORT & TECHNIGAZ SA
SSAB A SSAB AB CLASS A
MF WENDEL SE
SZG SALZGITTER AG
ITP INTERPARFUMS
FII LISI SA
FNAC FNAC DARTY SA
VOE VOESTALPINE AG
ACX ACERINOX SA
G24 SCOUT24 AG
ERA ERAMET SA
P2F PETROFAC LIMITED
IMPN IMPLENIA AG
POS PORR AG
GLB GLANBIA PLC
CFEB COMPAGNIE D'ENTREPRISES CFE SA
SUN SULZER AG
VRNL VERNEUIL PARTICIPATIONS
TUB TUBACEX S.A.
HEIJM HEIJMANS N.V. CERT
SOC
SIX2 SUBSEA 7 S.A.
CTAC SIXT SE
AIXA CTAC N.V.
NDA AIXTRON SE
FTON AURUBIS AG
WIE FEINTOOL INTERNATIONAL HOLDING AG
VLK WIENERBERGER AG
SBO VAN LANSCHOT KEMPEN NV CERT. OF SHS
SESL SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
AALB SES-IMAGOTAG SA
AMG AALBERTS N.V.
FDR AMG ADVANCED METALLURGICAL GROUP N.V.
SIGHT FLUIDRA S.A.
CON GENSIGHT BIOLOGICS SA
TGS CONZZETA AG
CSM TGS-NOPEC GEOPHYSICAL COMPANY ASA
TRE CORBION NV
IDR TECNICAS REUNIDAS SA
RIO INDRA SISTEMAS S.A. CLASS A
TEC RIO TINTO PLC
BHP TECHNIPFMC PLC
HOME BHP GROUP LTD
BFSA NEINOR HOMES SA
AMAG BEFESA SA
CAF AMAG AUSTRIA METALL AG
GRE CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
DSC1 GRENERGY RENOVABLES
HAG DUTCH STAR C SHAR
VK HENSOLDT AG
UPG VALLOUREC SA
AML UNIFIEDPOST GROUP
TE ASTON MARTIN LAGONDA GLOBAL HOLDINGS
EFIC1 TECHNIP ENERGIES NV
CTPNV EUROPEAN FINTECH IPO CO 1 BV
DEME CTP NV
SPM DEME GROUP NV
ADTN SAIPEM S.P.A.
TEN ADTRAN HOLDINGS INC
PLNW TENARIS S.A.
VIRI PLANISWARE
VIRIDIEN
Baptiste Salaville ... (+4)
  • Baptiste Salaville
  • Charlotte Vaisse
  • Emmanuel Matot
  • Marc Lavaud
NDX1 NORDEX SE
IPS IPSOS
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
SOP SOPRA STERIA GROUP SA
SLB.N SCHLUMBERGER NV
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
GTT GAZTRANSPORT & TECHNIGAZ SA
SSAB A SSAB AB CLASS A
MF WENDEL SE
SZG SALZGITTER AG
ITP INTERPARFUMS
FII LISI SA
FNAC FNAC DARTY SA
VOE VOESTALPINE AG
ACX ACERINOX SA
G24 SCOUT24 AG
ERA ERAMET SA
P2F PETROFAC LIMITED
IMPN IMPLENIA AG
POS PORR AG
GLB GLANBIA PLC
CFEB COMPAGNIE D'ENTREPRISES CFE SA
SUN SULZER AG
VRNL VERNEUIL PARTICIPATIONS
TUB TUBACEX S.A.
HEIJM HEIJMANS N.V. CERT
SOC
SIX2 SUBSEA 7 S.A.
CTAC SIXT SE
AIXA CTAC N.V.
NDA AIXTRON SE
FTON AURUBIS AG
WIE FEINTOOL INTERNATIONAL HOLDING AG
VLK WIENERBERGER AG
SBO VAN LANSCHOT KEMPEN NV CERT. OF SHS
SESL SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
AALB SES-IMAGOTAG SA
AMG AALBERTS N.V.
FDR AMG ADVANCED METALLURGICAL GROUP N.V.
SIGHT FLUIDRA S.A.
CON GENSIGHT BIOLOGICS SA
TGS CONZZETA AG
CSM TGS-NOPEC GEOPHYSICAL COMPANY ASA
TRE CORBION NV
IDR TECNICAS REUNIDAS SA
RIO INDRA SISTEMAS S.A. CLASS A
TEC RIO TINTO PLC
BHP TECHNIPFMC PLC
HOME BHP GROUP LTD
BFSA NEINOR HOMES SA
AMAG BEFESA SA
CAF AMAG AUSTRIA METALL AG
GRE CONSTRUCCIONES Y AUXILIAR DE FERROCARRILES S.A.
DSC1 GRENERGY RENOVABLES
HAG DUTCH STAR C SHAR
VK HENSOLDT AG
UPG VALLOUREC SA
AML UNIFIEDPOST GROUP
TE ASTON MARTIN LAGONDA GLOBAL HOLDINGS
EFIC1 TECHNIP ENERGIES NV
DEME EUROPEAN FINTECH IPO CO 1 BV
SPM DEME GROUP NV
ADTN SAIPEM S.P.A.
TEN ADTRAN HOLDINGS INC
PLNW TENARIS S.A.
VIRI PLANISWARE
VIRIDIEN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch